The vaccine, created to combat both smallpox and mpox, was registered by Russia’s health ministry in 2022 after clinical trials. According to Vektor, the trials demonstrated the vaccine’s safety and effectiveness, though specific results have not been published.
Russia’s consumer and health watchdog made mention of the demand from countries in the Eurasian Economic Union, the Commonwealth of Independent States, and African nations most affected by mpox outbreaks. However, it did not specify which countries have expressed interest.
